Caribou Biosciences
CRBU· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock 0.0% in FY2025
Rachel Haurwitz, Ph.D. is the CEO of Caribou Biosciences and was paid $1.8M in FY2025 (Dec), down 56%.
Pay$100 in the stock at the end of FY21 → $11
Executives3
See all- 1Rachel Haurwitz, Ph.D.President and chief executive officerFY2025
- 2Sriram Ryali, M.B.A.Chief financial officerFY2025
- 3Barbara McClung, J.D.Chief legal officerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCaribou Biosciences paid its 3 named executives $3.8M in total in FY2025 (Dec). CEO Rachel Haurwitz, Ph.D. was paid $1.8M of that.
| Name | |||
|---|---|---|---|
| Rachel Haurwitz, Ph.D.President and chief executive officer | |||
| Sriram Ryali, M.B.A.Chief financial officer | Not disclosed | Not disclosed | |
| Barbara McClung, J.D.Chief legal officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Caribou Biosciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Andrew Guggenhime, M.B.A.Chair · 2 yr on the boardIndependentAudit (Chair), Compensation (Chair)—Paid as an executive
- Natalie Sacks, M.D.Director · 5 yr on the boardIndependentNominating and Corporate Governance, Science and Technology—Paid as an executive
- Dara Richardson-Heron, M.D.Director · 2 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- David Johnson, M.B.A.Director · 1 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2023).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 10, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Mar 11, 2024 | FY2023 |
